Henry Ford Health System – Rheumatology
Primary Coordinator: Jenna Hudy 313-916-9328
- Indication: Systemic Lupus Erythematosus
- Enrollment Status: Open
- Protocol: ZB012-02-001
- Drug: Oblexelimab
- Sponsor: Zenas BioPharma
- Description: A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluated the efficacy and safety of Obexelimab in patients with systemic lupus eyrthematosus.